Safety of third dose of COVID-19 vaccination in frail patients: Results from the prospective Italian VAX4FRAIL study.

ABSTRACT:

Importance

Despite people with impaired immune competence due to an underlying disease or ongoing therapy, hereinafter frail patients, are (likely to be) the first to be vaccinated, they were usually excluded from clinical trials.

Objective

To report adverse reactions of frail patients after receipt of the third dose (booster) administered after completion of a two-dose mRNA vaccination and to compare with those reported after the receipt of the first two doses.

Design

A multicenter, observational, prospective study aimed at evaluating both the safety profile and the immune response of Pfizer-BioNTech or Moderna vaccines in frail patients.

Setting

National Project on Vaccines, COVID-19 and Frail Patients (VAX4FRAIL).

Participants

People consenting and in

SUBMITTER: Di Cosimo S 

PROVIDER: S-EPMC9631315 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature